DAC vs. No-DAC: The Structural Difference That Shapes Everything
CJC-1295 exists in two practical forms in the research-peptide market: with DAC (Drug Affinity Complex) and without DAC (also called Modified GRF 1-29). The DAC version has an additional modification that binds to serum albumin, extending the in-vivo half-life from approximately 30 minutes (for the non-DAC version) to approximately 6–8 days (PubMed: CJC-1295 Pharmacokinetics; see also NIH: Growth Hormone Releasing Peptides).
Because CJC-1295 with DAC requires an additional chemical modification step during synthesis, it is more costly to manufacture than the without-DAC variant. The molecular weight difference between with-DAC and without-DAC is unambiguously verifiable by mass spectrometry (LC-MS). Suppliers that do not publish mass-spectrometry confirmation or that provide only basic HPLC percentages cannot be cross-checked on whether the vial contains the DAC conjugate or the shorter Modified GRF 1-29 sequence.
| Factor | CJC-1295 No DAC (Modified GRF 1-29) | CJC-1295 With DAC |
|---|---|---|
| Structural Modification | Modified GHRH(1-29) analog without albumin-binding modification | Modified GHRH analog with Drug Affinity Complex (DAC) that binds to serum albumin |
| Published Half-Life | ~30 minutes | ~6–8 days (PubMed: CJC-1295 Pharmacokinetics) |
| GH Release Pattern | Short physiological pulses | Sustained basal GH/IGF-1 elevation |
| Co-Administration Context | Frequently discussed alongside GHRP-2, GHRP-6, or Ipamorelin | Long-acting analog producing sustained GH/IGF-1 elevation |
| Analytical Verification Requirement | LC-MS molecular mass confirmation alongside HPLC-UV purity is essential to prevent mislabeling between the two variants. | |
CJC-1295 No DAC Supplier Comparison
Below is our variant-specific supplier comparison for CJC-1295 No DAC (Modified GRF 1-29). Price and purity columns are omitted across all vendor tables; evaluations reflect COA availability, testing laboratory attribution, shipping speed, and notes from our source comparison. (For our #1 featured CJC-1295 supplier, see the Oath Research CJC-1295 and CJC-1295/Ipamorelin feature above; the verified public product list names CJC-1295 and CJC-1295/Ipamorelin and does not establish a DAC or No-DAC variant.)
| Supplier | COA Available | Testing Lab | Shipping | Notes |
|---|---|---|---|---|
| Limitless Life | Yes | Janoshik | 2–3 days | Fast, verified |
| Xpeptides | Yes | Janoshik | 3–5 days | Best verified value |
| Peptide Sciences | Yes | Third-party | Free shipping threshold available | Premium positioning |
| Swiss Chems | Yes | Colmaric | 3–4 days | Reliable mid-tier |
| Pure Rawz | Yes | Janoshik | Free shipping threshold available | Free ship threshold |
| Core Peptides | No | Internal claim | 5-7 days | No COA posted |
| US Research Peptides | On request | Third-party | 4–6 days | Must email for COA |
| Paradigm Peptides | Yes | Janoshik | 3–5 days | Consistent stock |
CJC-1295 With DAC Supplier Comparison
Availability for the DAC-conjugated variant is narrower across the market. Below is how the tracked variant-specific suppliers compare on CJC-1295 With DAC:
| Supplier | COA Available | Shipping | Stock Status |
|---|---|---|---|
| Limitless Life | Yes | 2–3 days | Regular stock |
| Peptide Sciences | Yes | Free shipping threshold available | Always available |
| Swiss Chems | Yes | 3–4 days | Regular stock |
| Xpeptides | Yes | 3–5 days | Intermittent stock |
| Pure Rawz | Yes | Free shipping threshold available | Regular stock |
| Core Peptides | N/A | N/A | Not stocked / Unavailable |
Why Oath Research Leads Our CJC-1295 Comparison
For CJC-1295 sourcing, Oath Research (score 94/100; Grade A, Recommended on RealPeptidesScores) publishes the most comprehensive documentation chain. The verified public product list names CJC-1295 and CJC-1295/Ipamorelin; it does not establish a DAC or No-DAC variant. Each batch carries a Certificate of Analysis from independent third-party laboratory Freedom Diagnostics reporting HPLC-UV purity, LC-MS molecular identity, and net peptide content, while citing USP <85> as its endotoxin standard. Across more than 500 batches tested in its archive at oathresearch.com/lab-results (as of October 2026), Oath maintains a 99.64% average purity over the trailing twelve months, with more than half of the certificates searchable by batch number without an account. Oath also publishes its physical street address (51 West Vaughn Ave Suite 205, Gilbert, AZ 85233) and US phone ((480) 999-1097), and provides a refund or replacement if a product fails stated specifications or arrives damaged.
Regulatory Context: FDA Bulk Drug Substances Status (As of April 22, 2026)
FDA's page current as of April 22, 2026 lists CJC-1295 as nominated but withdrawn. Withdrawal of a nomination is not FDA clearance or approval to compound CJC-1295 for human clinical use, and CJC-1295 is prohibited at all times in tested athletics under Category S2 of the WADA Prohibited List.
Related Desk Reports
- Ipamorelin Suppliers Compared — Companion comparison of selective pentapeptide GH secretagogue suppliers.
- Multi-Peptide Co-Administration Research Review — Receptor pharmacology of GHRH and ghrelin-mimetic pathways.
- Best-Value Peptides Comparison — Evaluating evidence and verification overhead across 12 compounds.
- Peptide Side Effects & Unknowns — Published adverse events for DAC vs. No-DAC GHRH analogs.